enVVeno Medical Corporation (NASDAQ:NVNO - Get Free Report) was the recipient of a large growth in short interest in May. As of May 15th, there was short interest totalling 469,500 shares, a growth of 19.4% from the April 30th total of 393,100 shares. Currently, 2.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 86,200 shares, the short-interest ratio is presently 5.4 days.
enVVeno Medical Trading Up 10.1%
NVNO traded up $0.35 on Friday, reaching $3.83. The company had a trading volume of 668,296 shares, compared to its average volume of 116,506. The company has a fifty day moving average of $3.07 and a 200-day moving average of $3.10. The company has a market capitalization of $67.16 million, a P/E ratio of -2.97 and a beta of 0.92. enVVeno Medical has a one year low of $2.03 and a one year high of $6.48.
enVVeno Medical (NASDAQ:NVNO - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported ($0.22) earnings per share (EPS) for the quarter. Research analysts predict that enVVeno Medical will post -1.32 EPS for the current year.
Hedge Funds Weigh In On enVVeno Medical
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd bought a new position in enVVeno Medical in the 1st quarter valued at about $80,000. Dauntless Investment Group LLC bought a new position in enVVeno Medical in the 1st quarter valued at about $186,000. Westside Investment Management Inc. boosted its position in shares of enVVeno Medical by 26.4% during the 1st quarter. Westside Investment Management Inc. now owns 259,050 shares of the company's stock valued at $681,000 after purchasing an additional 54,025 shares in the last quarter. Jane Street Group LLC bought a new position in shares of enVVeno Medical during the 4th quarter valued at about $56,000. Finally, Northern Trust Corp boosted its position in shares of enVVeno Medical by 68.3% during the 4th quarter. Northern Trust Corp now owns 56,725 shares of the company's stock valued at $171,000 after purchasing an additional 23,029 shares in the last quarter. Institutional investors own 34.71% of the company's stock.
About enVVeno Medical
(
Get Free Report)
enVVeno Medical Corporation Nasdaq: NVNO is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
Further Reading
Before you consider enVVeno Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enVVeno Medical wasn't on the list.
While enVVeno Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
